Artelo Biosciences Reports Q3 2026 Financial Results
Artelo Biosciences reported a Q3 2026 net loss of $1.8 million or $3.19 per basic and diluted common share, compared to a net loss of $3.1 million in Q3 2025. R&D expenses decreased to $0.8 million from $1.3 million year-over-year, while G&A expenses declined to $1.0 million from $1.8 million. The company ended the quarter with $4.4 million in cash.
Read source-backed brief